JPS63309149A - Production of gel or immobilized gel - Google Patents
Production of gel or immobilized gelInfo
- Publication number
- JPS63309149A JPS63309149A JP62142349A JP14234987A JPS63309149A JP S63309149 A JPS63309149 A JP S63309149A JP 62142349 A JP62142349 A JP 62142349A JP 14234987 A JP14234987 A JP 14234987A JP S63309149 A JPS63309149 A JP S63309149A
- Authority
- JP
- Japan
- Prior art keywords
- gel
- ions
- strontium
- sodium alginate
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000000661 sodium alginate Substances 0.000 claims abstract description 20
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 20
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 20
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229910001424 calcium ion Inorganic materials 0.000 claims abstract description 18
- 229910001427 strontium ion Inorganic materials 0.000 claims abstract description 17
- 102000004190 Enzymes Human genes 0.000 claims abstract description 9
- 108090000790 Enzymes Proteins 0.000 claims abstract description 9
- 244000005700 microbiome Species 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 8
- 210000004102 animal cell Anatomy 0.000 claims description 7
- 238000005728 strengthening Methods 0.000 claims description 4
- 238000007493 shaping process Methods 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 abstract description 11
- 229920000615 alginic acid Polymers 0.000 abstract description 11
- 229960001126 alginic acid Drugs 0.000 abstract description 6
- 239000000783 alginic acid Substances 0.000 abstract description 6
- 150000004781 alginic acids Chemical class 0.000 abstract description 6
- 238000005842 biochemical reaction Methods 0.000 abstract description 3
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 abstract description 2
- AEMOLEFTQBMNLQ-YBSDWZGDSA-N d-mannuronic acid Chemical compound O[C@@H]1O[C@@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-YBSDWZGDSA-N 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 43
- 239000000243 solution Substances 0.000 description 19
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 229910001631 strontium chloride Inorganic materials 0.000 description 6
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229910052712 strontium Inorganic materials 0.000 description 4
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical group [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000769 Isomerases Proteins 0.000 description 2
- 102000004195 Isomerases Human genes 0.000 description 2
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- DHEQXMRUPNDRPG-UHFFFAOYSA-N strontium nitrate Chemical compound [Sr+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O DHEQXMRUPNDRPG-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- -1 tyrosidase Proteins 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 102100032534 Adenosine kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 108700016171 Aspartate ammonia-lyases Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 1
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 108010036781 Fumarate Hydratase Proteins 0.000 description 1
- 102100036160 Fumarate hydratase, mitochondrial Human genes 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 108010036164 Glutathione synthase Proteins 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 108010043428 Glycine hydroxymethyltransferase Proteins 0.000 description 1
- 102000002667 Glycine hydroxymethyltransferase Human genes 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 108090000856 Lyases Proteins 0.000 description 1
- 102000004317 Lyases Human genes 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108010087702 Penicillinase Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102100033055 Transketolase Human genes 0.000 description 1
- 108010043652 Transketolase Proteins 0.000 description 1
- 108700040099 Xylose isomerases Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- FYPVXEILSNEKOO-UHFFFAOYSA-L calcium;butanoate Chemical compound [Ca+2].CCCC([O-])=O.CCCC([O-])=O FYPVXEILSNEKOO-UHFFFAOYSA-L 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950009506 penicillinase Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 1
- RXSHXLOMRZJCLB-UHFFFAOYSA-L strontium;diacetate Chemical compound [Sr+2].CC([O-])=O.CC([O-])=O RXSHXLOMRZJCLB-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Landscapes
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Jellies, Jams, And Syrups (AREA)
Abstract
Description
【発明の詳細な説明】
(産業上の利用分野)
本発明は、アルギン酸のゲル又は固定化ゲルを強化する
方法に関するものである。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to a method for strengthening alginic acid gels or immobilized gels.
更に詳細には1本発明は、カルシウムイオンで形成され
たアルギン酸のゲル又は固定化ゲルをストロンチウムイ
オンで処理し、ゲル又は固定化ゲルを強化する方法に関
するものである。More specifically, the present invention relates to a method of treating an alginic acid gel or immobilized gel formed with calcium ions with strontium ions to strengthen the gel or immobilized gel.
本発明において強化されたゲル又は固定化ゲルは燐酸等
を含む培養液によって脱弱化させることなく、長期間の
生化学的反応等に耐え得るもので、生化学界に益すると
ころ大なるものがある。The gel or immobilized gel strengthened in the present invention can withstand long-term biochemical reactions without being weakened by culture medium containing phosphoric acid, etc., and is of great benefit to the biochemical community. .
(従来の技術)
一般に、酵素、微生物、動物細胞等をアルギン酸ナトリ
ウム溶液に添加し、カルシウムイオンを含む溶液中に、
滴下したり、紡糸したりして、ゲル化して、生化学的反
応等に利用することはよく知られている。(Prior art) Generally, enzymes, microorganisms, animal cells, etc. are added to a sodium alginate solution, and the solution contains calcium ions.
It is well known that it can be applied dropwise or spun to form a gel and used for biochemical reactions and the like.
(発明が解決しようとする問題点)
しかし、従来のアルギン酸ナトリウムとカルシラムイオ
ンを反応させて得られたゲルが反応液中に含まれる種々
の塩類の影響、或いはPHの変化によってゲル強度が著
しく低下したり、リン酸イオン等のキレート剤の存在に
よりゲルが溶解してしまうという問題点があった。(Problems to be Solved by the Invention) However, the gel strength of the conventional gel obtained by reacting sodium alginate and calcilam ion is significantly reduced due to the influence of various salts contained in the reaction solution or changes in pH. There have been problems in that the gel is dissolved due to the presence of chelating agents such as phosphate ions.
そこでゲルの強度を向上させるため反応液中にカルシウ
ムイオンを多量に添加することも行われるが、多量のカ
ルシウムイオンによって、酵素、微生物、動物細胞等の
生化学的活性が阻害されるという問題が生じるのである
。Therefore, in order to improve the strength of the gel, large amounts of calcium ions are added to the reaction solution, but there is a problem that large amounts of calcium ions inhibit the biochemical activities of enzymes, microorganisms, animal cells, etc. It happens.
(問題点を解決するための手段)
本発明者らは、アルギン酸ゲルを長期間の培養等に耐え
る強固なものにするために鋭意研究をした結果、カルシ
ウムイオンを用いてゲル化したアルギン酸ゲルをストロ
ンチウムイオンで処理することによって1強固なアルギ
ン酸ゲルを得ることに成功したものである。(Means for Solving the Problems) As a result of intensive research to make alginate gel strong enough to withstand long-term culture, the present inventors have developed an alginate gel gelled using calcium ions. A strong alginate gel was successfully obtained by treatment with strontium ions.
本発明は、アルギン酸ナトリウム溶液をカルシウムイオ
ンで適宜形状に成型し、次いでストロンチウムイオンで
処理し1強化することを特徴とする強化されたゲルの製
造法である。The present invention is a method for producing a reinforced gel, which is characterized in that a sodium alginate solution is shaped into an appropriate shape with calcium ions, and then treated with strontium ions to be strengthened.
また、本発明は、生化学的活性体を添加したアルギン酸
ナトリウム溶液をカルシウムイオンで適宜形状に成型し
、次いでストロンチウムイオンで処理し、強化すること
を特徴とする強化された固定化ゲルの製造法である。The present invention also provides a method for producing a strengthened immobilized gel, which comprises shaping a sodium alginate solution containing a biochemically active substance into an appropriate shape with calcium ions, and then treating and strengthening it with strontium ions. It is.
本発明に使用するアルギン酸ナトリウムはカッ藻類中に
含まれるアルギン酸を化学操作により抽出しナトリウム
塩にしたもので、市販のアルギン酸ナトリウムなどいず
れも使用できる。しかしながら、アルギン酸は叶マンヌ
ロン酸(M)とL−グルロン酸CG)とから構成されて
いて、両者の成分比(M/G比)が物性に大きな影響を
与えている。The sodium alginate used in the present invention is a sodium salt obtained by extracting alginic acid contained in algae by chemical manipulation, and any commercially available sodium alginate can be used. However, alginic acid is composed of mannuronic acid (M) and L-guluronic acid (CG), and the ratio of these two components (M/G ratio) has a great influence on the physical properties.
そして、Mのみからなる部分、Gのみからなる部分1M
とGが混在する部分などがあるがゲル化剤の金属イオン
と結合して強固なゲルを形成するのは主としてGブロッ
クの働きによることが明らかとなっている。Then, a part consisting only of M, a part 1M consisting only of G
Although there are parts where G and G are mixed, it is clear that it is mainly the function of the G block that forms a strong gel by combining with the metal ions of the gelling agent.
本発明では、アルギン酸を構成するD−マンヌロン酸(
M)とL−グルロン酸(G)の比、すなわちM/G比が
0・1〜0・8、より好ましくは0.1〜0.2のもの
を選んで用いるのがよい。In the present invention, D-mannuronic acid (
It is preferable to select and use one having a ratio of M) to L-guluronic acid (G), that is, an M/G ratio of 0.1 to 0.8, more preferably 0.1 to 0.2.
この様なM/G比の低いアルギン酸ナトリウムは、G含
量の高い海藻類、若しくは多く含まれている部位[茎(
幹)部コ、及びとれた季節(5〜8月)を選択して抽出
調製するか、又はG含量の高いものをブレンドするなど
の方法によって、特別に調製して得ることができる。Sodium alginate with such a low M/G ratio can be used in seaweeds with high G content or in parts that contain a large amount [stem].
It can be obtained by special preparation, such as by extracting selected stems and the season (May to August), or by blending those with a high G content.
M/G比が上記範囲にあるものはゲル強度が大である。When the M/G ratio is within the above range, the gel strength is high.
本発明においては、カルシウムイオンで処理したアルギ
ン酸ゲルをストロンチウムイオンで処理することによっ
て、ゲルを強化することを特色とするものである。The present invention is characterized in that the alginate gel treated with calcium ions is treated with strontium ions to strengthen the gel.
カルシウムイオンとしては硝酸カルシウム、酢酸カルシ
ウム、乳酸カルシウム、酪酸カルシウム。Calcium ions include calcium nitrate, calcium acetate, calcium lactate, and calcium butyrate.
塩化カルシウム等が用いられる。又、ストロンチウムイ
オンとしては塩化ストロンチウム、硝酸ストロンチウム
、酢酸ストロンチウム等の水溶性の塩が用いられ、特に
塩化ストロンチウムが容易に入手できて使いやすい。Calcium chloride etc. are used. As the strontium ion, water-soluble salts such as strontium chloride, strontium nitrate, and strontium acetate are used, and strontium chloride is particularly easily available and easy to use.
具体的には、生化学的活性体を添加もしくは添加しない
アルギン酸ソーダの溶液をカルシウムイオンを含む溶液
で、粒状、繊維状等に成型した後、その成型ゲルをスト
ロンチウムイオンを含む溶液で処理して、燐酸等に対し
て強化されるものである。Specifically, a solution of sodium alginate with or without biochemically active substances is molded into granules, fibers, etc. with a solution containing calcium ions, and then the molded gel is treated with a solution containing strontium ions. , phosphoric acid, etc.
ナトリウムと置換したカルシウムの一部又は大部分がス
トロンチウムと置き換ったり、新たにストロンチウムが
残ったナトリウムと置換したり、更にはこれらの組合せ
も起り、全体としてゲルが燐酸等に対して強化されるも
のと考えられるが、カルシウムイオンでゲル化して、更
にストロンチウムイオンで処理することによって、ゲル
が燐酸等に対して強化される理由の詳細は不明である。Some or most of the calcium that replaced sodium may be replaced with strontium, strontium may be newly replaced with remaining sodium, or a combination of these may occur, resulting in the gel being strengthened against phosphoric acid, etc. as a whole. However, the details of why the gel is strengthened against phosphoric acid and the like by gelling with calcium ions and further treating with strontium ions are unknown.
アルギン酸ナトリウムの濃度は、0.5 (W/V)%
〜8(W/V)%濃度が良く、より好ましくは0.8(
W/V)%〜3(W/V)%濃度である。The concentration of sodium alginate is 0.5 (W/V)%
A concentration of ~8 (W/V)% is good, more preferably 0.8 (
The concentration is from 3(W/V)% to 3(W/V)%.
また、アルギン酸ナトリウム溶液に添加される生化学的
活性体としては、酵素、微生物、動物細胞、植物細胞な
どがある。Biochemically active substances added to the sodium alginate solution include enzymes, microorganisms, animal cells, and plant cells.
酵素としては、アルコールデビドロゲナーゼ、D−アミ
ノ酸オキシダーゼ、カタラーゼ等の酸化還元酵素、トラ
ンスケトラーゼ、アデニレートキナーゼ、ヘキソキナー
ゼ等の転移酵素、β−ガラクトシダーゼ、ペニシリナー
ゼ、リパーゼ、エステラーゼなどの加水分解酵素、フマ
ラーゼ、アスパルターゼ、スレオニンアルドラーゼ、β
−チロシダーゼなどのリアーゼ酵素、グルコースイソメ
ラーゼ、アラニンイソメラーゼなどの異性化酵素、グル
タチオンシンターゼ、グルタミンシンターゼなどのりガ
ーゼ酵素などがあげられる。Examples of enzymes include oxidoreductases such as alcohol dehydrogenase, D-amino acid oxidase, and catalase, transferases such as transketolase, adenylate kinase, and hexokinase, and hydrolyzing enzymes such as β-galactosidase, penicillinase, lipase, and esterase. Enzymes, fumarase, aspartase, threonine aldolase, β
- Lyase enzymes such as tyrosidase, isomerase enzymes such as glucose isomerase and alanine isomerase, and glue gauze enzymes such as glutathione synthase and glutamine synthase.
又、微生物としては細菌、酵母、カビ、放線菌などの酵
素活性を有する微生物であれば特に限定されることはな
く、また、動物細胞としては、各種生理活性物質を生産
する細胞株、抗体を生産するハイブリドーマなどがあり
、更に植物細胞としは各種生理活性物質を生産する細胞
がある。Microorganisms are not particularly limited as long as they have enzymatic activity such as bacteria, yeast, molds, and actinomycetes. Animal cells include cell lines that produce various physiologically active substances and antibodies. There are hybridomas that produce bioactive substances, and plant cells that produce various physiologically active substances.
生化学的活性体は0.01〜50%、好ましくは0.1
〜20%程度アルギン酸ナトリウム溶液に添加され、混
合される。ただし、動物細胞の場合は、アルギン酸ナト
リウム溶液1++1に対しl X 10’〜lX10’
。The biochemically active form is 0.01-50%, preferably 0.1
~20% is added to the sodium alginate solution and mixed. However, in the case of animal cells, l x 10' to l x 10' for 1++1 sodium alginate solution.
.
好ましくはI X 10’〜5 X 108個添加され
る。Preferably, I x 10' to 5 x 108 pieces are added.
生化学的活性体を添加、もしくは添加しないアルギン酸
ナトリウム溶液は次の1〜3の方法等でゲル化される。A sodium alginate solution with or without the addition of a biochemically active substance is gelated by methods 1 to 3 below.
ゲル化に用いるカルシウムイオンの濃度は0.01〜1
.0モル濃度程度で、好ましくは0.02〜0.3モル
濃度程度である。The concentration of calcium ions used for gelation is 0.01-1
.. The concentration is about 0 molar, preferably about 0.02 to 0.3 molar.
!、 注射器やピペット等のノズルからカルシウムイオ
ンを含有する水溶液中に滴下することによりビーズ状の
ゲルが得られる。! A bead-shaped gel can be obtained by dropping it into an aqueous solution containing calcium ions from a nozzle such as a syringe or pipette.
2、 カルシウムイオンを含有する水溶液中で注射器、
ピペット等のノズルから連続的に吐出させることにより
繊維状のゲルが得られる。2. Syringe in an aqueous solution containing calcium ions,
A fibrous gel can be obtained by continuously discharging it from a nozzle such as a pipette.
3、平板上にキャストするか濾紙もしくはガーゼなどに
含浸させた後、水溶液中のカルシウムイオンと接触させ
ることにより膜状のゲルを得ることができる。3. After casting on a flat plate or impregnating filter paper or gauze, a membrane-like gel can be obtained by contacting with calcium ions in an aqueous solution.
ここに得られたゲルはストロンチウムイオンを含む溶液
に浸漬したり、該溶液を噴霧したりして処理される。ス
トロンチウムイオンの濃度は0.01〜1.0モル、好
ましくは0.02〜0.3モル程度である。The gel thus obtained is treated by immersing it in a solution containing strontium ions or by spraying the solution. The concentration of strontium ions is about 0.01 to 1.0 mol, preferably about 0.02 to 0.3 mol.
処理時間は 1分〜1時間、PI(3〜11、温度4〜
50℃程度である。Processing time is 1 minute to 1 hour, PI (3 to 11, temperature 4 to
The temperature is about 50°C.
本発明のストロンチウムイオンで強化処理されたアルギ
ン酸ゲルは燐酸に対して強い抵抗力をもつようになる。The alginate gel reinforced with strontium ions of the present invention has strong resistance to phosphoric acid.
動物細胞株、ハイブリドーマ等をゲル中に含有させた場
合、培養液にリン酸緩衝液を使用するので、特に有効で
ある6即ち、ストロンチウムイオンで強化処理したもの
は1週間以上の長期間リン酸緩衝液に浸漬しても崩壊し
ないがストロンチウムイオンで強化処理しないものはリ
ン酸緩衝液に浸漬して1日以内ですべて崩壊してしまう
ものである。When animal cell lines, hybridomas, etc. are contained in the gel, it is particularly effective because a phosphate buffer is used as the culture medium. Materials that do not disintegrate when immersed in a buffer solution, but are not reinforced with strontium ions, completely disintegrate within one day after being immersed in a phosphate buffer solution.
次に本発明の実施例を示す。Next, examples of the present invention will be shown.
実施例1゜
2%アルギン酸ナトリウム溶液100mAに、市販のマ
ウス細胞(大日本製薬に、に製)にBリンパ球を常法に
より融合したハイブリドーマ培養懸濁液を1、OX 1
0’ケ/gゲルになるように添加、混合し、注射器につ
め、氷水中の0.1M塩化カルシウム溶液に滴下し、6
0分放置し1粒状化ゲルを得た。Example 1 A hybridoma culture suspension in which B lymphocytes were fused to commercially available mouse cells (manufactured by Dainippon Pharmaceutical Co., Ltd.) using a conventional method was added to 100 mA of a 2% sodium alginate solution.
Add and mix to make 0'kg/g gel, fill in a syringe, drop into 0.1M calcium chloride solution in ice water,
One granulated gel was obtained after being left for 0 minutes.
得られたゲルを無血清RDF培地で3日間37℃で静置
培養した。The obtained gel was statically cultured at 37° C. for 3 days in serum-free RDF medium.
さらに粒状化ゲルを5つに分けて、氷水中の0゜IN塩
化ストストロンチウム溶液分、5分、 10分。Furthermore, the granulated gel was divided into 5 parts and added to 0°IN strontium chloride solution in ice water for 5 minutes and 10 minutes.
20分、30分それぞれ浸漬した。It was immersed for 20 minutes and 30 minutes, respectively.
得られた各強化ゲルを無血清RDF培地で3日間37℃
で静置培養し、グルコースの消費量をみた。Each of the obtained reinforced gels was incubated in serum-free RDF medium for 3 days at 37°C.
The cells were cultured statically and the amount of glucose consumed was measured.
結果は表1辷示される。The results are shown in Table 1.
3日後に各々のゲルを250wMリン酸緩衝液(pH7
,2)に浸したところ、ストロンチウム未処理のゲルは
30分以内に溶解したが、ストロンチウム処理したゲル
は1週間後においてもその形状に変化はなかった、又、
ストロンチウム処理は細胞に影響を及ぼさなかった。After 3 days, each gel was soaked in 250 wM phosphate buffer (pH 7).
, 2), the strontium-untreated gel dissolved within 30 minutes, but the strontium-treated gel did not change its shape even after one week.
Strontium treatment had no effect on the cells.
実施例2゜
2%アルギン酸ナトリウム溶液100IIQに市販の幼
ハムスター腎細胞(大日本製薬に、Kl)を4.7 X
106ケ/gゲルになるように添加、混合し、注射器
につめ、氷水中の0.1M塩化カルシウム溶液に滴下し
、60分放置し、粒状化ゲルを得た。Example 2 Commercially available young hamster kidney cells (Kl from Dainippon Pharmaceutical Co., Ltd.) were added to 2% sodium alginate solution 100IIQ at 4.7X.
The mixture was added and mixed at a concentration of 106 gels/g, filled into a syringe, added dropwise to a 0.1M calcium chloride solution in ice water, and left to stand for 60 minutes to obtain a granulated gel.
得られたゲルをカラムにつめ、3%グルコース添加BM
E培地300mQづつを毎日とりかえながら65日間3
0℃で循環培養し、グルコース消費量を測定し。The resulting gel was packed into a column and 3% glucose added to BM.
3 for 65 days, changing 300 mQ of E medium every day.
Circulating culture was carried out at 0°C, and glucose consumption was measured.
65日間後ゲルを取り出し、氷水中の0.1M塩化スト
ロンチウム溶液に20分間浸漬し、後再びカラムにつめ
、3%グルコース添加BME培地300tQづつを毎日
とりかえながらあと10日間30℃で循環培養し、グル
コース消費量を測定した。その結果は第1図に示される
が、この図から塩化ストロンチウムによる処理が細胞に
全く影響を及ぼさないことがわかる。After 65 days, the gel was taken out, immersed in a 0.1M strontium chloride solution in ice water for 20 minutes, and then packed into a column again and cultured in circulation at 30°C for another 10 days, replacing 300 tQ of BME medium supplemented with 3% glucose every day. Glucose consumption was measured. The results are shown in Figure 1, which shows that treatment with strontium chloride has no effect on the cells.
第1図は実施例2において塩化ストロンチウムによる処
理が細胞に与する影響をみた図である。FIG. 1 is a diagram showing the effect of treatment with strontium chloride on cells in Example 2.
Claims (1)
宜形状に成型し、次いでストロンチウムイオンで処理し
、強化することを特徴とする強化されたゲルの製造法。 2、生化学的活性体を添加したアルギン酸ナトリウム溶
液をカルシウムイオンで適宜形状に成型し、次いでスト
ロンチウムイオンで処理し、強化することを特徴とする
強化された固定化ゲルの製造法。 3、アルギン酸ナトリウムがM/G比0.1〜0.8の
アルギン酸ナトリウムである特許請求の範囲第1項又は
第2項記載のゲル又は固定化ゲルの製造法。 4、生化学的活性体が酵素、微生物、動物細胞又は植物
細胞であることを特徴とする特許請求の範囲第2項記載
の固定化ゲルの製造法。[Claims] 1. A method for producing a reinforced gel, which comprises molding a sodium alginate solution into an appropriate shape with calcium ions, and then treating and strengthening it with strontium ions. 2. A method for producing a strengthened immobilized gel, which comprises shaping a sodium alginate solution containing a biochemically active substance into an appropriate shape with calcium ions, and then treating and strengthening it with strontium ions. 3. The method for producing a gel or immobilized gel according to claim 1 or 2, wherein the sodium alginate is sodium alginate with an M/G ratio of 0.1 to 0.8. 4. The method for producing an immobilized gel according to claim 2, wherein the biochemically active substance is an enzyme, a microorganism, an animal cell, or a plant cell.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62142349A JPS63309149A (en) | 1987-06-09 | 1987-06-09 | Production of gel or immobilized gel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62142349A JPS63309149A (en) | 1987-06-09 | 1987-06-09 | Production of gel or immobilized gel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63309149A true JPS63309149A (en) | 1988-12-16 |
| JPH0468896B2 JPH0468896B2 (en) | 1992-11-04 |
Family
ID=15313302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62142349A Granted JPS63309149A (en) | 1987-06-09 | 1987-06-09 | Production of gel or immobilized gel |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63309149A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5930398A (en) * | 1982-08-11 | 1984-02-17 | Matsushita Electric Ind Co Ltd | speaker |
-
1987
- 1987-06-09 JP JP62142349A patent/JPS63309149A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5930398A (en) * | 1982-08-11 | 1984-02-17 | Matsushita Electric Ind Co Ltd | speaker |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0468896B2 (en) | 1992-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4950600A (en) | Method of immobilizing enzymes or microbes with alginate having a low mannuronic acid to guluronic acid ratio | |
| JPS6321474B2 (en) | ||
| JPS59113889A (en) | Preparation of immobilized enzyme or immobilized microbial cell | |
| US5290692A (en) | Bioadaptable porous crystalline glass containing an immobilized fibrinolytic enzyme for dissolving blood clots | |
| JPH01115901A (en) | Production of gel or hardened gel | |
| EP0056111B1 (en) | Immobilized enzymatic active substance and method for preparing the same | |
| JPH0468896B2 (en) | ||
| JPS6331538A (en) | Immobilizing carrier | |
| JPS5974984A (en) | Preparation of immobilized enzyme or microorganism | |
| US3860486A (en) | Insolubilizing enzymes with polystyrene derivatives | |
| JPS60180588A (en) | Preparation of immobilized complex of microorganism having plant pathogen-controlling activity | |
| Okeson et al. | Glutamine replenishment and ammonia removal in hybridoma cell cultures via immobilized glutamine synthetase | |
| JPH05168481A (en) | Preparation method of immobilized gel including biocatalyst and its use | |
| Karube et al. | Bacteriolysis by immobilized enzymes | |
| JPS596884A (en) | Manufacturing method of immobilized enzyme | |
| SU722197A1 (en) | Process for producing immobilized enzymes | |
| JPS63160584A (en) | Production of immobilized enzyme or immobilized microorganism | |
| CA1150654A (en) | Process for the production of citric acid | |
| JPH0371880B2 (en) | ||
| JPS6012037B2 (en) | Production method of itaconic acid using immobilized microorganisms | |
| JPS62158484A (en) | Production of immobilized enzyme | |
| Hagiwara et al. | Fibrin membrane endowed with biological function VII. An approach to an artificial liver; Conversion of ammonia to urea invitro | |
| JPH0376578A (en) | Immobilized yeast fungal cell | |
| EP0931142B1 (en) | Method and immobilized biocatalyst for the production of l(-) malic acid | |
| JPS6147194A (en) | Preparation of n-carbamoyl-d-valine or d-valine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |